» Articles » PMID: 37694344

Duration of Untreated Illness in Gambling Disorder

Overview
Journal CNS Spectr
Specialties Neurology
Psychiatry
Date 2023 Sep 11
PMID 37694344
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Gambling disorder is common, affects 0.5-2% of the population, and is under-treated. Duration of untreated illness (DUI) has emerged as a clinically important concept in the context of other mental disorders, but DUI in gambling disorder, has received little research scrutiny.

Methods: Data were aggregated from previous clinical trials in gambling disorder with people who had never previously received any treatment. DUI was quantified, and clinical characteristics were compared as a function of DUI status.

Results: A total of 298 individuals were included, and the mean DUI (standard deviation) was 8.9 (8.4) years, and the median DUI was 6 years. Longer DUI was significantly associated with male gender, older age, earlier age when the person first started to gamble, and family history of alcohol use disorder. Longer DUI was not significantly associated with racial-ethnic status, gambling symptom severity, current depressive or anxiety severity, comorbidities, or disability/functioning. The two groups did not differ in their propensity to drop out of the clinical trials, nor in overall symptom improvement associated with participation in those trials.

Conclusions: These data suggest that gambling disorder has a relatively long DUI and highlight the need to raise awareness and foster early intervention for affected and at-risk individuals. Because earlier age at first gambling in any form was strongly linked to longer DUI, this highlights the need for more rigorous legislation and education to reduce exposure of younger people to gambling.

Citing Articles

The Interplay of Pathological Gambling, Substance Abuse, and Financial Ruin: A Case Report.

R S, C S, Jetty R, John De Britto J, R A Cureus. 2024; 16(9):e69684.

PMID: 39429253 PMC: 11490279. DOI: 10.7759/cureus.69684.


Transforming global approaches to chronic disease prevention and management across the lifespan: integrating genomics, behavior change, and digital health solutions.

Thomas S, Browning C, Charchar F, Klein B, Ory M, Bowden-Jones H Front Public Health. 2023; 11:1248254.

PMID: 37905238 PMC: 10613497. DOI: 10.3389/fpubh.2023.1248254.

References
1.
Furey M, Nugent A, Speer A, Luckenbaugh D, Hoffman E, Frankel E . Baseline mood-state measures as predictors of antidepressant response to scopolamine. Psychiatry Res. 2012; 196(1):62-7. PMC: 3464046. DOI: 10.1016/j.psychres.2012.01.003. View

2.
Kim S, Grant J, Potenza M, Blanco C, Hollander E . The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res. 2009; 166(1):76-84. PMC: 3641525. DOI: 10.1016/j.psychres.2007.11.008. View

3.
Kim S, Grant J, Adson D, Shin Y, Zaninelli R . A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002; 63(6):501-7. DOI: 10.4088/jcp.v63n0606. View

4.
Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62. PMC: 495331. DOI: 10.1136/jnnp.23.1.56. View

5.
Altamura A, Camuri G, DellOsso B . [Understanding the role of the duration of untreated illness in psychiatric disorders: a narrative review]. Riv Psichiatr. 2010; 45(4):197-208. View